{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:48:34Z","timestamp":1792097314806,"version":"4.4.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.bulcan.2026.08.009","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:34:50Z","timestamp":1792096490000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Recommandations du Groupe Francophone des My\u00e9lodysplasies (GFM) - Approche diagnostique et prise en charge des syndromes my\u00e9lodysplasiques, des leuc\u00e9mies my\u00e9lomonocytaires chroniques et du syndrome VEXAS"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0514-5789","authenticated-orcid":false,"given":"Sophie","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel","family":"Ad\u00e8s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Kosmider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orianne","family":"Wagner-Ballon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Bardet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Gyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Chapuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Baptiste","family":"Micol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Dubow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyne","family":"Chartier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aline","family":"Renneville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin-Pierre","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Bidet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Dimicoli-Salazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"S\u00e9bert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lise","family":"Larcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Freiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Meunier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibault","family":"Comont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9-Miguel","family":"Torregrosa-Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Denneti\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Odile","family":"Rauzy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliette","family":"P\u00e9nichoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Cluzeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Peterlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u00ebl","family":"Heiblig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Willekens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Garnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rapha\u00ebl","family":"Itzykson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ars\u00e8ne","family":"Mekinian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Robin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maud","family":"D\u2019Aveni-Piney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Anne","family":"Hospital","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatiha","family":"Chermat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Fontenay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Fenaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.bulcan.2026.08.009_bib0225","first-page":"103409","article-title":"Cytogenetics in the management of myelodysplastic neoplasms (myelodysplastic syndromes, MDS): Guidelines from the groupe francophone de cytog\u00e9n\u00e9tique h\u00e9matologique (GFCH)","volume":"71","author":"Auger","year":"2023","journal-title":"Curr Res Transl Med"},{"issue":"7","key":"10.1016\/j.bulcan.2026.08.009_bib0230","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200008","article-title":"Molecular international prognostic scoring system for myelodysplastic syndromes","volume":"1","author":"Bernard","year":"2022","journal-title":"NEJM Evid"},{"issue":"4","key":"10.1016\/j.bulcan.2026.08.009_bib0235","doi-asserted-by":"crossref","first-page":"472","DOI":"10.3324\/haematol.2014.112755","article-title":"Multicentric study underlining the interest of adding CD5, CD7\u00a0and CD56\u00a0expression assessment to the flow cytometric Ogata score in myelodysplastic syndromes and myelodysplastic\/myeloproliferative neoplasms","volume":"100","author":"Bardet","year":"2015","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.bulcan.2026.08.009_bib0240","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1038\/leu.2013.178","article-title":"Flow cytometric detection of dyserythropoiesis: a sensitive and powerful diagnostic tool for myelodysplastic syndromes","volume":"27","author":"Mathis","year":"2013","journal-title":"Leukemia"},{"issue":"23","key":"10.1016\/j.bulcan.2026.08.009_bib0245","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1182\/blood-2015-01-620781","article-title":"Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia","volume":"125","author":"Selimoglu-Buet","year":"2015","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.bulcan.2026.08.009_bib0250","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.bulcan.2026.08.009_bib0255","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200310","article-title":"Prediction of risk for myeloid malignancy in clonal hematopoiesis","volume":"2","author":"Weeks","year":"2023","journal-title":"NEJM Evid"},{"issue":"19","key":"10.1016\/j.bulcan.2026.08.009_bib0260","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1182\/blood.2024024756","article-title":"Risk prediction for clonal cytopenia: multicenter real-world evidence","volume":"144","author":"Xie","year":"2024","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.bulcan.2026.08.009_bib0265","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1038\/s41588-023-01472-1","article-title":"Multiparameter prediction of myeloid neoplasia risk","volume":"55","author":"Gu","year":"2023","journal-title":"Nat Genet"},{"issue":"2","key":"10.1016\/j.bulcan.2026.08.009_bib0270","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1701719","article-title":"Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease","volume":"377","author":"Jaiswal","year":"2017","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.bulcan.2026.08.009_bib0275","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1182\/blood-2016-01-583625","article-title":"How I treat MDS and AML in Fanconi anemia","volume":"127","author":"Peffault de Latour","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bulcan.2026.08.009_bib0280","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/s41375-025-02814-0","article-title":"DDX41-mutant myeloid neoplasms defy current prognostic schemes and require a dedicated risk scoring system: a multicenter, retrospective study","volume":"40","author":"Gurnari","year":"2026","journal-title":"Leukemia"},{"issue":"24","key":"10.1016\/j.bulcan.2026.08.009_bib0285","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1200\/JCO.19.00181","article-title":"Stopping leukemia in its tracks: Should preemptive hematopoietic stem-cell transplantation be offered to patients at increased genetic risk for acute myeloid leukemia?","volume":"37","author":"Hamilton","year":"2019","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.bulcan.2026.08.009_bib0290","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022\u00a0recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.bulcan.2026.08.009_bib0295","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.bulcan.2026.08.009_bib0300","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1182\/blood-2016-05-714030","article-title":"Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia","volume":"128","author":"Elena","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2026.08.009_bib0305","doi-asserted-by":"crossref","DOI":"10.1200\/JCO-25-02116","article-title":"Molecular-based ecosystem to improve personalized medicine in chronic myelomonocytic leukemia","author":"Lanino","year":"2026","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.bulcan.2026.08.009_bib0310","first-page":"2047","article-title":"Consensus proposal for revised International Working Group 2023\u00a0response criteria for higher-risk myelodysplastic syndromes","volume":"141","author":"Zeidan","year":"2023","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.bulcan.2026.08.009_bib0315","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1182\/blood-2018-06-857102","article-title":"Proposals for revised IWG 2018\u00a0hematological response criteria in patients with MDS included in clinical trials","volume":"133","author":"Platzbecker","year":"2019","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.bulcan.2026.08.009_bib0320","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1038\/s41375-018-0118-9","article-title":"A phase 3\u00a0randomized, placebo-controlled study assessing the efficacy and safety of epoetin-alpha in anemic patients with low-risk MDS","volume":"32","author":"Fenaux","year":"2018","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.bulcan.2026.08.009_bib0325","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1056\/NEJMoa1908892","article-title":"Luspatercept in patients with lower-risk myelodysplastic syndromes","volume":"382","author":"Fenaux","year":"2020","journal-title":"N Engl J Med"},{"issue":"10399","key":"10.1016\/j.bulcan.2026.08.009_bib0330","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S0140-6736(23)00874-7","article-title":"Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial","volume":"402","author":"Platzbecker","year":"2023","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.bulcan.2026.08.009_bib0335","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1182\/blood.2022016171","article-title":"Longer-term benefit of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes with ring sideroblasts","volume":"140","author":"Zeidan","year":"2022","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.bulcan.2026.08.009_bib0340","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.1182\/blood-2011-01-330126","article-title":"A randomized phase 3\u00a0study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-\/Intermediate-1-risk myelodysplastic syndromes with del5q","volume":"118","author":"Fenaux","year":"2011","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.bulcan.2026.08.009_bib0345","doi-asserted-by":"crossref","first-page":"e659","DOI":"10.1016\/S2352-3026(24)00142-X","article-title":"Low dose lenalidomide versus placebo in non-transfusion dependent patients with low risk, del(5q) myelodysplastic syndromes (SintraREV): a randomised, double-blind, phase 3\u00a0trial","volume":"11","author":"D\u00edez-Campelo","year":"2024","journal-title":"Lancet Haematol"},{"issue":"10423","key":"10.1016\/j.bulcan.2026.08.009_bib0350","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0140-6736(23)01724-5","article-title":"Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3\u00a0trial","volume":"403","author":"Platzbecker","year":"2024","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.bulcan.2026.08.009_bib0355","doi-asserted-by":"crossref","first-page":"513","DOI":"10.7326\/M19-0916","article-title":"Iron chelation in transfusion-dependent patients with low- to intermediate-1-risk myelodysplastic syndromes: a randomized trial","volume":"172","author":"Angelucci","year":"2020","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.bulcan.2026.08.009_bib0360","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.bulcan.2026.08.009_bib0365","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2026.08.009_bib0370","doi-asserted-by":"crossref","unstructured":"Garcia-Manero G, Platzbecker U, Fenaux P, Roboz GJ, Fong CY, Hus M, et al. Subgroup analyses from the randomized, phase 3\u00a0VERONA study of venetoclax with azacitidine versus placebo with azacitidine in patients with treatment-na\u00efve, intermediate and higher-risk myelodysplastic syndromes. 67th American Society of Hematology Annual Meeting; 2025\u00a0Dec 6-9; Orlando (FL), USA. Abstract 235.","DOI":"10.1182\/blood-2025-235"},{"issue":"7","key":"10.1016\/j.bulcan.2026.08.009_bib0375","doi-asserted-by":"crossref","first-page":"e521","DOI":"10.1016\/S2352-3026(23)00090-X","article-title":"CPX-351\u00a0in higher risk myelodysplastic syndrome and chronic myelomonocytic leukaemia: a multicentre, single-arm, phase 2\u00a0study","volume":"10","author":"Peterlin","year":"2023","journal-title":"Lancet Haematol"},{"issue":"24","key":"10.1016\/j.bulcan.2026.08.009_bib0380","doi-asserted-by":"crossref","first-page":"5272","DOI":"10.1158\/1078-0432.CCR-22-1183","article-title":"Outcomes in patients with poor-risk cytogenetics with or without TP53\u00a0mutations treated with venetoclax and azacitidine","volume":"28","author":"Pollyea","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.bulcan.2026.08.009_bib0385","doi-asserted-by":"crossref","first-page":"e150","DOI":"10.1097\/HS9.0000000000000150","article-title":"Diagnosis and treatment of chronic myelomonocytic leukemias in adults: recommendations from the European Hematology Association and the European LeukemiaNet","volume":"2","author":"Itzykson","year":"2018","journal-title":"Hemasphere"},{"issue":"6","key":"10.1016\/j.bulcan.2026.08.009_bib0390","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1038\/s41375-021-01207-3","article-title":"Chronic myelomonocytic leukemia diagnosis and management","volume":"35","author":"Chan","year":"2021","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.bulcan.2026.08.009_bib0395","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1200\/JCO.22.00437","article-title":"Decitabine versus hydroxyurea for advanced proliferative chronic myelomonocytic leukemia: results of a randomized phase III trial within the EMSCO Network","volume":"41","author":"Itzykson","year":"2023","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.bulcan.2026.08.009_bib0400","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1002\/art.43287","article-title":"American College of Rheumatology Guidance Statement for Diagnosis and Management of VEXAS Developed by the International VEXAS Working Group Expert Panel","volume":"78","author":"Mekinian","year":"2026","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"10.1016\/j.bulcan.2026.08.009_bib0405","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/blood.2022016642","article-title":"Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study","volume":"140","author":"Heiblig","year":"2022","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.bulcan.2026.08.009_bib0410","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1136\/ard-2024-225640","article-title":"Efficacy and safety of targeted therapies in VEXAS syndrome: retrospective study from the FRENVEX","volume":"83","author":"Hadjadj","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.bulcan.2026.08.009_bib0415","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1182\/blood.2024028133","article-title":"Efficacy and safety of azacitidine for VEXAS syndrome: a large-scale retrospective study from FRENVEX","volume":"146","author":"Jachiet","year":"2025","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bulcan.2026.08.009_bib0420","doi-asserted-by":"crossref","first-page":"e70156","DOI":"10.1002\/hem3.70156","article-title":"Efficacy of erythroid-stimulating agent and luspatercept in VEXAS syndrome: a multicenter retrospective study by the FRENVEX group","volume":"9","author":"Heiblig","year":"2025","journal-title":"Hemasphere"},{"issue":"30","key":"10.1016\/j.bulcan.2026.08.009_bib0425","doi-asserted-by":"crossref","first-page":"3318","DOI":"10.1200\/JCO.20.02724","article-title":"Comparison between 5-azacytidine treatment and allogeneic stem-cell transplantation in elderly patients with advanced MDS according to donor availability (VidazaAllo Study)","volume":"39","author":"Kr\u00f6ger","year":"2021","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.bulcan.2026.08.009_bib0430","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1038\/leu.2015.37","article-title":"HLA-matched allogeneic stem cell transplantation improves outcome of higher risk myelodysplastic syndrome. A prospective study on behalf of SFGM-TC and GFM","volume":"29","author":"Robin","year":"2015","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.bulcan.2026.08.009_bib0435","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1182\/bloodadvances.2025017035","article-title":"Transplantation in patients with lower-risk MDS: a prospective phase 2\u00a0trial based on donor availability","volume":"10","author":"S\u00e9bert","year":"2026","journal-title":"Blood Adv"},{"issue":"8","key":"10.1016\/j.bulcan.2026.08.009_bib0440","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1002\/ajh.26620","article-title":"Treosulfan compared with reduced-intensity busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients: final analysis of a prospective randomized trial","volume":"97","author":"Beelen","year":"2022","journal-title":"Am J Hematol"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000745512600408X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000745512600408X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:34:56Z","timestamp":1792096496000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000745512600408X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":44,"alternative-id":["S000745512600408X"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2026.08.009","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recommandations du Groupe Francophone des My\u00e9lodysplasies (GFM) - Approche diagnostique et prise en charge des syndromes my\u00e9lodysplasiques, des leuc\u00e9mies my\u00e9lomonocytaires chroniques et du syndrome VEXAS","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2026.08.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}